181 related articles for article (PubMed ID: 19403900)
1. Rationing antiretroviral therapy in Africa--treating too few, too late.
Ford N; Mills E; Calmy A
N Engl J Med; 2009 Apr; 360(18):1808-10. PubMed ID: 19403900
[No Abstract] [Full Text] [Related]
2. Initiation of antiretroviral therapy among pregnant women in resource-limited countries: CD4+ cell count response and program retention.
Toro PL; Katyal M; Carter RJ; Myer L; El-Sadr WM; Nash D; Abrams EJ;
AIDS; 2010 Feb; 24(4):515-24. PubMed ID: 19996939
[TBL] [Abstract][Full Text] [Related]
3. HIV clinics are halting enrolment of new patients as funding stalls, MSF warns.
Roehr B
BMJ; 2009 Jul; 339():b2966. PubMed ID: 19620230
[No Abstract] [Full Text] [Related]
4. Effects of the change from Stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: studies on mitochondrial toxicity and thymic function.
Rosso R; Nasi M; Di Biagio A; Repetto E; Dentone C; Pinti M; Nemes E; Ferraresi R; Mussini C; Esposito R; Viscoli C; Cossarizza A
Pediatr Infect Dis J; 2008 Jan; 27(1):17-21. PubMed ID: 18162932
[TBL] [Abstract][Full Text] [Related]
5. The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily.
Tung MY; Mandalia S; Bower M; Gazzard B; Nelson M
HIV Med; 2005 May; 6(3):151-4. PubMed ID: 15876280
[TBL] [Abstract][Full Text] [Related]
6. Simplifying and adapting antiretroviral treatment in resource-poor settings: a necessary step to scaling-up.
Calmy A; Klement E; Teck R; Berman D; Pécoul B; Ferradini L
AIDS; 2004 Dec; 18(18):2353-60. PubMed ID: 15622311
[No Abstract] [Full Text] [Related]
7. Improvement of dyslipidemia during different HAART regimens: tenofovir- versus stavudine-containing antiretroviral combinations.
Manfredi R
Clin Infect Dis; 2006 May; 42(9):1345-7; author reply 1347-8. PubMed ID: 16586399
[No Abstract] [Full Text] [Related]
8. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
Antinori A; Trotta MP; Nasta P; Bini T; Bonora S; Castagna A; Zaccarelli M; Quirino T; Landonio S; Merli S; Tozzi V; Di Perri G; Andreoni M; Perno CF; Carosi G
Antivir Ther; 2006; 11(2):233-43. PubMed ID: 16640104
[TBL] [Abstract][Full Text] [Related]
9. Transmission of multidrug-resistant HIV-1: 5 years of immunological and virological survey.
Delaugerre C; Marcelin AG; Soulié C; Chaix ML; Katlama C; Girard PM; Calvez V; Morand-Joubert L
AIDS; 2007 Jun; 21(10):1365-7. PubMed ID: 17545716
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of patients taking tenofovir DF with low-level HIV-1 viremia and the K65R substitution in HIV-1 RT.
Chappell BJ; Margot NA; Miller MD
AIDS; 2007 Mar; 21(6):761-3. PubMed ID: 17413698
[TBL] [Abstract][Full Text] [Related]
11. Hard choices: rationing antiretroviral therapy for HIV/AIDS in Africa.
Rosen S; Sanne I; Collier A; Simon JL
Lancet; 2005 Jan 22-28; 365(9456):354-6. PubMed ID: 15664233
[No Abstract] [Full Text] [Related]
12. CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.
Wolbers M; Battegay M; Hirschel B; Furrer H; Cavassini M; Hasse B; Vernazza PL; Bernasconi E; Kaufmann G; Bucher HC;
Antivir Ther; 2007; 12(6):889-97. PubMed ID: 17926643
[TBL] [Abstract][Full Text] [Related]
13. [Tenofovir in Study 903. Also effective and tolerable in first-line therapy].
MMW Fortschr Med; 2002 Aug; 144(33-34):61. PubMed ID: 12380158
[No Abstract] [Full Text] [Related]
14. Five-year data out on Viread.
AIDS Patient Care STDS; 2006 Dec; 20(12):887-8. PubMed ID: 17219618
[No Abstract] [Full Text] [Related]
15. The cost effectiveness of antiretroviral treatment strategies in resource-limited settings.
Bishai D; Colchero A; Durack DT
AIDS; 2007 Jun; 21(10):1333-40. PubMed ID: 17545710
[TBL] [Abstract][Full Text] [Related]
16. [Complete HAART in a single pill. New milestone for improving compliance].
MMW Fortschr Med; 2008 Apr; 150 Spec No 1():40-1. PubMed ID: 19024916
[No Abstract] [Full Text] [Related]
17. Case study: an active, 24-year-old woman positive for HIV.
JAAPA; 2006 Jan; Suppl():14. PubMed ID: 16429964
[No Abstract] [Full Text] [Related]
18. Tenofovir: Gilead applies for approval; expanded access liberalized.
Gilden D
AIDS Treat News; 2001 May; (364):2-3, 1. PubMed ID: 11569959
[TBL] [Abstract][Full Text] [Related]
19. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients.
Milinkovic A; Martinez E; López S; de Lazzari E; Miró O; Vidal S; Blanco JL; Garrabou G; Laguno M; Arnaiz JA; Leon A; Larrousse M; Lonca M; Mallolas J; Gatell JM
Antivir Ther; 2007; 12(3):407-15. PubMed ID: 17591031
[TBL] [Abstract][Full Text] [Related]
20. Secure antiretroviral therapy delivery in a resource-limited setting: streamlined to minimize drug resistance and expense.
Kitkungvan D; Apisarnthanarak A; Laowansiri P; Mundy LM
HIV Med; 2008 Oct; 9(8):636-41. PubMed ID: 18643857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
